Alembic Pharmaceuticals Ltd. - Research Center
533573 APLLTD Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | Sep ' 18 | |
|---|---|---|---|---|---|
| Sales | 2,459.46 | 2,658.44 | 2,100.92 | 2,031.64 | 1,906.85 |
| Operating profit | 513.93 | 879.49 | 617.37 | 585.50 | 520.62 |
| Interest | 6.44 | 8.42 | 13.90 | 11.29 | 5.92 |
| Gross profit | 510.93 | 874.07 | 734.77 | 577.67 | 516.87 |
| EPS (Rs) | 17.76 | 33.93 | 28.94 | 22.49 | 19.37 |
Half yearly
results in details
| Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | Sep ' 18 | |
|---|---|---|---|---|---|
| Other income | 3.45 | 3.00 | 131.30 | 3.46 | 2.17 |
| Stock adjustment | 11.37 | -25.97 | -76.88 | -99.62 | -47.89 |
| Raw material | 534.06 | 579.59 | 506.35 | 471.78 | 441.47 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 528.39 | 499.73 | 409.09 | 397.28 | 321.57 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 871.71 | 725.60 | 644.99 | 676.70 | 671.08 |
| Provisions made | - | - | - | - | - |
| Depreciation | 88.03 | 72.55 | 70.66 | 65.00 | 51.54 |
| Taxation | 73.86 | 134.59 | 108.62 | 88.76 | 100.28 |
| Net profit / loss | 349.05 | 666.93 | 545.49 | 423.91 | 365.05 |
| Extra ordinary item | - | - | -10.00 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 39.31 | 39.31 | 37.70 | 37.70 | 37.70 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 20.90 | 33.08 | 29.39 | 28.82 | 27.30 |
| GPM (%) | 20.75 | 32.84 | 32.92 | 28.39 | 27.08 |
| NPM (%) | 14.17 | 25.06 | 24.44 | 20.83 | 19.12 |
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis